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In order to study differences in antigen expression related to the different 
stages of the process of metastasis of human melanoma cell lines, we 
determined the expression pattern of a series of well-characterized genes in a 
set of human melanoma cell lines with different metastatic behavior in nude 
mice. This set included non-metastatic (IF6, 530), sporadically metastatic 
(M14, Mel 57), and frequently metastatic (BLM, MV3) cell lines after 
subcutaneous inoculation, To study the phenotype of these cell lines both the 
cultured cells and representative samples of local tumors at the inoculation 
site and their metastases in the lungs were immunostained with a panel of 
monoclonal antibodies directed against melanocytic differentiation or progres­
sion antigens. Although most cell lines (IF6, 530, M14 and Mel 57) showed 
HLA-DR expression in vitro, these antigens were lacking in all xenografted 
lesions studied with exception of the 530 cell line. 530 Xenografts, however, 
showed a dramatic down-regulation of HLA-DR compared with the cell line 
in vitro. The same phenomenon was seen with respect to ICAM-1 expression. 
The expression of all other antigens studied in xenografts, both in subcutan­
eous tumors and in lung lesions, was in general comparable to that in the 
melanoma cell lines in vitro, with exception of the 530 cell line. In all 
melanoma cell lines except 530 the degree of intra- and interlesional hetero­
geneity regarding the expression of all antigens studied was limited. Remark­
ably, comparison of the immunophenotype of the frequently metastasizing 
(BLM, MV3) and the sporadically (M14, Mel 57) or non-metastasizing (IF6, 
530) cell lines showed that the two frequently metastasizing cell lines had 
marked expression of the progression antigens VLA-2 and epidermal growth 
factor receptor, and lack of expression of the differentiation antigen NKI- 
beteb. These findings warrant further studies on the role of these antigens in 
the process of metastasis of human melanoma cells in nude mice.
Introduction
A number of monoclonal antibodies (MAbs) have been developed that 
recognize antigens expressed by human melanocytic cells. These melanoma- 
associated antigens (MAAs) include differentiation antigens, progression anti­
gens and other antigens, such as functional antigens. Differentiation antigens are
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expressed both in benign and malignant melanocytic lesions while progression 
antigens preferentially are expressed in one or few stages in the process of 
tumor progression [3, 12, 30, 31].
The various phenotypic profiles of the different stages of tumor progression in 
human melanocytic lesions have been obtained by compiling the data of large 
numbers of different lesions derived from different patients. In order to be able 
to study subsequent stages of tumor progression in one individual we have 
chosen to use the nude mouse model employing human melanoma cells. A 
second important reason to u$e the nude mouse in research on tumor progres­
sion is that genetic manipulation (e.g, transfection experiments) can be per­
formed to study the role of candidate genes in the pathogenesis of metastasis in 
an in vivo system. For these purposes we decided to use a panel of human 
melanoma cell lines with different biological behavior in nude mice. This 
approach seemed feasible as some human melanoma cell lines were shown to be 
highly metastatic after subcutaneous (s.c.) or intravenous (i.v.) inoculation [10,
17, 24].
Based on the foregoing we have studied the immunophenotype of metastasiz­
ing and non-metastasizing human melanoma cells xenografted into nude mice 
using a set of MAbs directed against MAAs. In particular we looked for 
differences in antigen expression (1) between the cell lines in vitro and in vivo 
(cultured cells vs s.c. tumors in nude mice), (2) between s.c. tumors and lung 
metastases in nude mice, and (3) between the different cell lines in relation to 
their metastatic behavior in nude mice.
Materials and methods
Nude mice
BALB/c athymic nude mice (nu/nu) were purchased from the Laboratory 
Breeding and Research Center, Gl. Bomholtgaard, Ry, Denmark or bred in the 
nude mouse facility of the Central Animal Laboratories, University of Nij­
megen. Animals were kept in separate rooms in cages covered with air filters 
under specific pathogen-free conditions. The mice were used when 4-6 weeks 
old. Within a single experiment the mice were sex and age matched.
Human melanoma cell lines
BLM is a subline of BRO [24] (gift from Dr B. Giovanella, Stehlin 
Foundation, Houston, TX), isolated from a lung metastasis produced after s.c. 
inoculation of BRO cells. This subline possesses a higher metastatic potential 
than the parental BRO cell line. M14 [17] was a gift from Dr A. Cochran (John 
Wayne Clinic, Johnsson Comprehensive Cancer Center, UCLA School of 
Medicine, Los Angeles, CA). IF6 was developed in our laboratory from a 
melanoma metastasis in an axillary lymph node of a 35-year-old male patient 
(unpublished data). Mel 57 [5] was developed by Dr J. Brüggen (Münster, 
Germany) and was kindly provided by Dr J. de Vries (The Netherlands Cancer 
Institute, Amsterdam). 530 [38] was kindly provided by Dr P. I. Schrier 
(University Hospital, Leiden, The Netherlands). MV3 was derived from a 
cutaneous melanoma metastasis of a 76-year-old male patient after three cycles 
of in vivo passaging in nude mice [35] .
All cell lines were grown as monolayers in culture flasks on Dulbecco’s
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modified Eagle medium supplemented with 10% fetal calf serum, glutamine, 
penicillin G and streptomycin.
Preparation of tumor cell suspension for in vivo injections
Tumor cells were harvested from subconfluent cultures by overlaying of the 
monolayers with a solution of 0*25% trypsin and 0-02% EDTA. After about 
2 min the flasks were tapped sharply to dislodge the cells. Cells were washed 
twice with serum containing culture medium and then suspended in the 
appropriate concentration in phosphate-buffered saline (PBS).
Tumor cell injections
To produce xenografts at the inoculation site and to produce pulmonary 
métastasés (spontaneous métastasés) mice were inoculated s.c. with 1-2 X 106 
tumor cells in a volume of 0*1 ml in the lateral thoracic wall [20]. The mice were 
inspected twice a week for local tumor growth and general condition. The
number of s.c. injected mice ranged from 25 (MV3) to 60 (BLM).
To produce pulmonary tumor colonies (experimental métastasés) l-2x 106 
tumor cells in a volume of 0*1 ml were injected i,v. into the lateral tail vein. The 
number of i.v. injected mice ranged from 15 (530) to 45 (M14).
After s.c. and after i.v. inoculation mice were killed when signs of illness or 
respiratory distress were noted. Mice that remained healthy were killed 3-4 
months after inoculation.
Detection of lung métastasés
At autopsy all visceral organs were inspected. The tumor at the inoculation 
site, the lungs, spleen, liver and kidney and lymph nodes were taken for 
histopathological examination. Tissue fragments were; (a) fixed in 4% neutral 
formalin and embedded in paraffin for microscopic examination of hematoxylin 
and eosin stained 4/¿m sections or (b) snap-frozen and stored at -70°C for 
immunohistochemical analysis. As micrometastases can be missed by macro­
scopic examination only, paraffin sections from at least three different levels of 
the lungs were microscopically examined. From the other organs one represen­
tative section was examined.
Monoclonal antibodies
MAbs recognizing different MAAs or HLA antigens were used. Their 
antigenic specificity, their presumed role in melanoma biology and their source 
are listed in Tablet. All MAbs were purified from ascites fluid by affinity 
chromatography using a protein A-Sepharose column (Pharmacia, Uppsala, 
Sweden)* All MAbs except anti-EGFR (2E9) were directly conjugated to 
horseradish peroxidase (HRPO) as described by Nakane and Pierce [27].
Immunocytochemical staining
To determine the immunocytochemical staining profile of the cell lines in 
vitro incubations were performed both on cytospin preparations and on cells 
grown on cover slips. Immunoperoxidase staining of xenograft lesions was 
performed on 4 fim frozen sections. The staining procedure was as follows: after 
acetone fixation preparations were incubated with directly HRPO-labeled MAb
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Table 1. Monoclonal antibodies used in this study.
Monoclonal
antibody Antigen Biological role Reference
NKI-beteb gpl00-107 MAA differentiation [37]
K1.2 9♦ MAA progression [32]
A1.43 Integrin MAA progression [4, 19]
VLA-2 Cell-matrix, cell-cell adhesion
Muc 18 gpll3 MAA progression [21, 221
Ig-superfamily
15.75 gp75 MAA progression [15]
PAL-M1 Transferrin MAA progression [30, 361
receptor Cellular proliferation
CL203.4 ICAM-1 MAA progression [26, 33]
Adhesion
B8.11.2 HLA-DR Immune regulation [23]
W6.32 HLA-ABC Immune regulation [2]
NKI-M9 MACAM-1 Cellular adhesion m
PAL-M2 p95-100 Cellular adhesion [30]
2E9 EGFR MAA progression [6,8]
in an appropriate dilution for 1 h at room temperature. After washing they were 
stained using 3-amino-9-ethylcarbazole as chromogen. Preparations were coun­
terstained with Harris hematoxylin and mounted for microscopic inspection. As 
negative controls identical incubations were done with an irrelevant HRPO- 
labeled MAb. Cytospin preparations and cover slips of all cell lines were also 
stained using an indirect immunoperoxidase technique. Xenografts were not 
stained by the indirect immunoperoxidase technique, as the binding of rabbit 
anti-mouse HRPO to the mouse tissue caused a strong aspecific signal that 
interfered with the interpretation of the antigen expression on the tumor cells.
Percentages of positive cells were estimated by two independent observers 
and expressed in classes indicating the percentage of positive cells: 0 (no positive 
cells), 1-5 (max. 5% positive cells), 6-20, 21-40, 41-60, 61-80, 81-100.
Results
Tumor take and metastasis rate
All cell lines used developed tumors at the s.c. inoculation site (Figure 1). 
Tumor growth after s.c. inoculation was most rapid with MV3 cells (tumor 
appearance after 10 days) and slowest with 530 cells (tumor appearance after 40 
days). After 3-4 months tumor size in the 530 cell line inoculated mice was 
small (i.e. 10 mm diameter). Subcutaneous inoculation of the 530 cell line did 
not result in spontaneous metastasis. Even 6-7 months after s.c. inoculation 
lung metastases could not be found (not shown). After i.v. inoculation of 530 
cells in 80% of the mice lung colonies were found (Figure 2A). M14, Mel 57, 
BLM (Figure 2B), and MV3 not only produced experimental metastases but also 
spontaneous metastases in 5, 15, 50 and 90% of the cases, respectively. No 
metastases were found in any of the other tissues examined. In Figure 3 the 
mean values of the number of lung metastases or lung colonies per three lung 
sections (see Materials and methods) is shown. In general, lung colonies from 
530 cells are numerous and are small in size (Figure 2C) while the other cell
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Figure 1.
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Diagram representing the percentage of tumor take and the metastasis rate of
melanoma cell lines studied.
lines developed a relatively small number of lesions in the lungs; however, these 
lesions are larger in size.
Comparison of antigen expression in vitro and in s.c. xenograft lesions
To determine the expression of MAAs and of HLA class I and II antigens the 
staining profile of all six cell lines and their xenografted s.c. lesions (= inocul­
ate) was studied. Antigen expression of each cell line both in vitro and in 
xenograft lesions was tested at least three times. Detailed positive staining 
results of all cell lines and their xenografts are summarized in Figure 4. MAbs 
that showed negative staining results with both the cell line and the xenograft 
lesions from a particular cell line are not depicted in the figure.
In s.c. xenograft lesions expression of the melanoma-associated differentiation 
marker NKI-beteb, of most progression and functional antigens, and of HLA 
class I was in general similar to the expression in the cell lines in vitro 
(Figure 4). Marked differences in expression between the cell lines in vitro and 
their s.c. xenograft lesions were seen with respect to HLA class II (B.8.11.2) 
and ICAM-1 (CL203.4). HLA class II antigens were detected on all cell lines in 
a moderate to high percentage of cells, except the M14 cell line where only a 
few cells were positive and the BLM and MV3 cell lines which were completely 
negative. In xenografts of all cell lines, except the 530 cell line, expression of 
HLA class II was not detectable in any of the lesions. In 530 tumors grown at 
the inoculation site 10-40% of the tumor cells were positive showing a diffuse 
distribution pattern.
ICAM-1 expression was found on all cell lines in a high percentage of cells. 
In xenografts of all cell lines ICAM-1 expression was not detectable, indicating a 
complete down-regulation of ICAM-1 expression.
Less striking but also remarkable was the difference in expression of 
NKI-beteb in the 530 xenograft lesions in comparison with the cultured cell line. 
While in vitro only very few cells were positive, in xenografts collected from the 
s.c. inoculation site nests of strongly positive cells were seen while only a small 
part of the surrounding tumor cells was stained (Figure 5A).
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Figure 2. Lung métastasés after inoculation of human melanoma cells. (A) Macroscopic 
preparation of the lungs from a mouse i.v. inoculated with 530 cells, Note the numerous 
lung colonies, (B) Macroscopic preparation of the lungs from a mouse s.c, inoculated with 
BLM  cells. Note the tumor cell nodules which are visible on the lung surface.
(C) Microscopic section from the lungs shown in (A). x'160.
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shown in Figure 4) was seen on BLM and MV3 cells in vitro while all other cell 
lines were negative. Only M14 cells showed very faint staining. No xenograft 
lesions were stained with anti-EGFR due to absence of a directly labeled 
antibody.
Comparison of antigen expression between s.c. tumors and lung métastasés
To determine whether any of the antigens studied may be specifically 
expressed as a consequence of the metastasizing process we also compared 
antigen expression of s.c. tumors and lung métastasés, both experimental and
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Figure 3. Diagram representing the mean value of the number of lung lesions counted in
three lung sections from three different levels of the lungs.
spontaneous. Except the 530 cell line, all cell lines that gave rise to lung 
colonization (i.v. inoculation) and/or lung metastasis (s.c. inoculation) showed 
(nearly) identical expression patterns in s.c. tumors and lung lesions (Figure 4), 
With respect to the 530 cell line we found that expression of some antigens (e.g. 
NKI-beteb, NKI-M9) was variable. Although expression in s.c. tumors was 
rather constant, in the lungs colonies were seen which were either completely 
negative, partly positive or completely positive, often very strongly (Figure 5B).
As in s.c, tumors, lung lesions of all cell lines except 530 showed strong or 
complete down-regulation of both HLA class II and ICAM-1 expression. In lung 
colonies of the 530 cell line expression of HLA class II was absent in most 
lesions. A few lesions showed only scattered weakly positive cells. However, we 
found one very strongly positive tumor lesion localized at the visceral pleura 
(Figure 5C).
A remarkable difference in expression of Muc 18 antigen between the s.c. 
tumor and the lung lesions was seen with Mel 57 cells. While s.c. tumors and 
lung colonies were clearly positive spontaneous metastases showed positive as 
well as negative lesions.
Comparison of metastasizing and non-metastasizing cell lines
The data presented in Figure 1 indicate that we used a panel of human 
melanoma cell lines with different biological behavior in nude mice, especially 
with different capacities to form spontaneous lung metastases: IF6 and 530 do 
not produce spontaneous lung metastases, M14 and Mel 57 only sporadically, 
and BLM and MV3 frequently. When we evaluate the potency of the cell lines 
to form spontaneous metastases and their immunophenotype in vitro we see that 
absence of NKI-beteb and HLA class II and marked expression of EGFR and 
VLA-2 antigen (BLM and MV3) is associated with a high capacity to form 
spontaneous metastases (Table 2). An inverse expression pattern of these 
antigens in vitro is associated with no or very low metastatic ability (IF6, 530, 
M14 and Mel 57).
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Discussion
In this study we used a panel of human melanoma cell lines with different 
biological behavior in nude mice ranging from non-metastatic (IF6), moderate 
metastatic (530, M14 and Mel 57) to highly metastatic (BLM and MV3).
Our immunocytochemical results show that the nude mouse provides a good 
model to study the phenotype of metastasizing or colonizing human tumor cells 
in subsequent stages of the process of dissemination in one individual. With 
respect to the expression of the antigens studied we found that the expression 
pattern in xenograft lesions was in general similar to the expression on the cell 
lines in vitro. We found only few exceptions; the most striking being the lack of 
HLA-DR antigen expression in xenografted lesions produced after s.c. as well as
i.v. inoculation of all cell lines but one, the 530 cell line.
That this phenomenon is selective is strongly suggested by the fact that HLA 
class I and most MAAs tested showed a staining pattern in all xenografts that 
was in general similar to that in the melanoma cell lines in vitro, The lack of 
HLA class II expression could be explained by clonal outgrowth of class II 
negative cells. However, this seems unlikely because the growth behavior of the 
class II negative BLM cell line showed no large differences with other, class II 
positive, cell lines. In addition, expression of HLA-DR can be reinduced by 
culturing melanoma cells derived from HLA-DR negative xenograft lesions (own 
observation). Another explanation for the dramatical down-regulation in the 
xenografts may be the presence of some factors in the tumor environment or the 
lack of human inducing factors, e.g. IFN-gamma [13]. Recent evidence has 
shown that lymphokines such as IFN-gamma induce the expression of HLA class 
II antigens in cells of the melanocytic lineage [9, 11, 14, 25, 28]. In addition, 
recently it was shown that in vivo administration of recombinant IFN-gamma to 
nude mice bearing human tumor xenografts can result in an induction of 
HLA-DR expression on the tumor cells ([1], own observation). A third
Table 2. Relation between biological behavior of human melanoma cell lines in nude mice
and expression of MAAs.
Lung metastasis Expression of MAAs •
Cell line Exp. (%) Spont. (%) HLA-DR EGFR VLA-2 NKI-beteb
IF6 0 0 4- —
(30-50)
i  j u r n
(70-90)
530 80 0 + — +
( 80-100)
+/—
(1-5) (1-5)
M14 50 5 4- — +
\
(1-5) (80-100) (20-40)
Mel 57 60 15 4- — — +
(20-40) (80-100)
BLM 60 50 — 4-4- 4-4* -
(80-100) (80-100)
MV3 100 90 ------ 4. 4 . 4-4- —
(80-100) (80-100)
—, Negative staining; +/—, very weak staining; 4-, moderate staining; + 4-, strong 
staining. Percentage of tumor cells stained is shown in parentheses.
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explanation may be that the presence of human melanoma cells in nude mice 
may give rise to a change in the differentiation stage of the melanoma cells. 
However, concerning the melanoma cell lines studied no changes in stage of 
differentiation in xenografts could be detected. The results with the 530 cell line 
indicate that lack of expression of class II in the xenografts of the other cell lines 
is not a complete switch-off of the HLA class II genes, but suggest that there is 
a dramatic down-regulation of the expression. The expression of HLA class II in 
part of the 530 cells in xenograft lesions may be caused by constitutive 
expression of the gene in these cells instead of an inducible expression in the 
other cells. A down-regulation as seen for HLA-DR was also found for ICAM-1 
in xenograft lesions. Previous studies as well as our own observations (not 
published) have shown that on melanocytic cells expression of ICAM-1, just as 
HLA-DR, is susceptible to modulation by IFN-gamma [26, 33],
Mainly based on the marked higher expression of ICAM-1 in melanoma 
metastases than in primary melanomas it was suggested that ICAM-1 could have 
a functional role in the process of dissemination [16, 25]. However, in our 
animal model system we did not find an induction of ICAM-1 expression in 
metastatic lesions indicating that in this system there seems no important role 
for this adhesion molecule in metastasis. In addition, if ICAM-1 plays a role in 
metastasis formation in nude mice, human ICAM-1 should recognize the active 
site of its counter structure, mouse LFA-1. To the best of our knowledge until 
now no data are available with respect to this cross-reactivity.
In all melanoma cell lines studied except 530, the degree of intra- and 
interlesional heterogeneity regarding the expression of MAAs and HLA antigens 
is limited. This is in line with recent data showing that there is a limited 
heterogeneity within fresh human melanoma lesions [8], which may reflect clonal 
overgrowth [18]. The intra- and interlesional heterogeneity of 530 xenograft 
tumors may be explained by the fact that this cell line has only recently been 
developed.
In a recent study Rodolfo et al [29] reported data on the growth behavior of 
early cell cultures of different primary and metastatic melanomas in nude mice. 
In that study they also described the tumor cell phenotype of these early 
cultures between the third and eighth in vitro culture generation for HLA class I 
and II and some MAAs using an indirect immunodetection technique. With 
respect to the expression of melanocytic differentiation markers, HLA-ABC, 
HLA-DR and ICAM-1 in vitro their results are in agreement with ours.
Our experiments suggest that there is a striking difference in expression of the 
progression markers VLA-2, EGFR and HLA class II and of the differentiation 
antigen NKI-beteb in vitro between cell lines with different biological behavior 
in nude mice. Expression of the first two antigens and lack of expression of the 
latter two is associated with the capacity to form spontaneous lung metastases. 
However lack of expression of HLA class II does not seem to play a crucial role 
in the biological behavior of the tumor cells in the in vivo model system because 
expression of this antigen is completely switched-off or dramatically down-regul­
ated in all xenograft lesions. Whether the expression of VLA-2 and EGFR and 
lack of expression of NKI-beteb are really involved in spontaneous metastasis 
formation has to be proven. With respect to the intracellular antigen NKI-beteb 
we suppose that lack of expression in BLM and MV3 has been caused by loss of 
differentiation of the melanoma cells.
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The melanoma-associated progression antigens identified so far have been 
defined by the correlation of their expression with human melanocytic tumor 
progression and in part (e.g. HLA class II) for their ability to predict the 
appearance of métastasés or unfavorable outcome [3, 34]. This implicates that 
these markers are candidates for molecules which may play a role in the 
pathogenesis of metastasis in human melanoma. Our study showed that cell lines 
(BLM and MV3) with high metastatic capacity express few of the markers of 
tumor progression while the less aggressive cell line (IF6) expresses most of 
these antigens. This negative correlation between the number of progression 
markers expressed and the degree of malignancy is not in line with the 
correlation found in the human melanocytic system. Therefore, it is not certain 
if these markers play a role in the process of metastasis. It is conceivable that 
they are involved in clonal expansion. Furthermore, as already pointed out for 
ICAM-1, all of the interactions which should occur between the tumor cells and 
other cells or tissue structures, in metastasis formation of human tumors in the 
nude mouse are heterologous. Therefore, whatever interactions are occurring, 
only those where ligand-ligand interactions are well conserved between these 
species may be relevant for the human situation. These interactions may be 
mainly limited to cell-substrate interactions (e.g. EGF and EGFR; extracellular 
matrix components and their receptor molecules) rather than cell-cell inter­
actions. With respect to our data this means that only some of the antigens 
studied, e.g. EGFR and VLA-2, may have relevance in the human situation. 
Further studies using transfected human melanoma cells are in progress to 
obtain more evidence for the role of these gene products in the pathogenesis of 
metastasis.
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